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Summary The use of different expressions of mortality in prostate cancer can lead to difficulty in comparing reported data. We have used different measures of mortality in the same group of 438 patients presenting consecutively with histologically proven adenocarcinoma of the prostate, in order to assess the values and deficiencies of each method. The use of expected and relative survival is shown to be valuable in allowing indirect but objective assessment of disease specific mortality in prostatic cancer.
Prostatic cancer presents at an age when concurrent disease is
common, and therefore the interpretation of survival data in
men with this disease is complicated by the need to take
some account of age-related general mortality. Surprisingly,
many reports considering aspects of survival in this disease
fail to give adequate, if any, details of the age structure of
the group of patients being reported (Parker et al., 1985;
Merrick et al., 1985; Paulson & Walther, 1989).
The problem of expressing disease specific mortality in
prostate cancer has been addressed by a number of workers
and different approaches have been used. While some
authors have used relative survival (the ratio of observed to
expected survival at a given time) to express disease specific
mortality (Wilson et al., 1984; Johansson et al., 1989), others
(George, 1988) present survival curves of 'objective' and
'possible' deaths due to prostate cancer, by excluding 'non-
cancer deaths' on the basis of hospital records. Some report
deaths due to 'unrelated causes', but do not define the
methods used to ascertain cause of death (Parker et al.,
1985).
National reports of death rates from prostate cancer are
based on the certified cause of death as registered with the
General Register Office of Scotland and with the equivalent
offices elsewhere in the UK, and while the general trends
illustrated by the use of such data are of undoubted value,
the validity and reliability of the certified cause of death is
open to question. Most authors avoid the use of certification
data in survival analysis, but since national mortality statis-
tics represent the largest body of data used to report mor-
tality in prostate cancer it is appropriate to consider this
method of measuring outcome along with other measures of
mortality.
The use of these different methods in reporting survival
can lead to difficulty in comparing and interpreting reported
data from different sources. In this study we have used a
number of methods to analyse the survival of a group of
patients with prostate cancer in order to assess the relative
value of each method.
Patients and methods
Between January 1978 and September 1988 there were 438
consecutive new cases of histologically confirmed adenocar-
cinoma of the prostate in the University Department of
Surgery (WGH) and Department of Urology at the Western
General Hospital in Edinburgh. They have been followed up
regularly as described previously (Goodman et al., 1988)
until death or to date. All were primary referrals. Patients
diagnosed elsewhere and subsequently followed at WGH
over the same period are excluded from the following
analysis, as are five patients with 'endometroid' carcinoma of
the prostate, and nine patients with a clinical picture of
advanced prostate cancer in whom histological confirmation
proved impossible before death.
Correspondence: C.M. Goodman.
Received 21 June 1989; and in revised form 18 September 1989.
Survival probabilities based on partially censored observa-
tions were calculated by life table methods (Peto et al., 1977). Expected survival was calculated for each patient in the series
by reference to current life tables for Scottish males for the
year of presentation (Annual Reports of the Registrar General for Scotland, 1978-88). Although the expectation of
life throughout this age range has increased slightly since
1978 (and is likely to continue to do so) the changes were
calculated to be small enough to avoid the use of cohort life
tables, which reflect this changing risk (Armitage & Berry, 1987).
A part of the abridged life table for Scottish males in 1987
is shown in Table 1. These published tables show the
numbers surviving to an exact age x of a hypothetical group of 10,000 men exposed throughout life to the mortality pro- babilities indicated by the estimated population, and the total
deaths registered, in the corresponding year. The same data
are shown in graphical form in Figure 1. The probability of
surviving 5 and 10 years at age x can be derived from these
data by computing the proportion of men aged x who sur-
vive to the ages of x + 5 and x + 10 years. The survival
probabilities calculated in this way are shown in Figure 2.
The survival probabilities for ages between the 5-year inter-
vals given in the abridged life table are derived by interpola- tion. Above the age of 85 years, survival probability cannot
be computed directly from these tables, and so here we have
estimated the approximate probabilities by extrapolation to
zero at 100 years. The precise magnitude of the small error
incurred by this compromise, which applies to only 18
patients in this series, is difficult to estimate. Reference to less
freely available data than the abridged life table suggests the
error is negligible in this group. In each group or subgroup of patients the expected 5 and 10 year survival is calculated
by dividing the sum of the individual probabilities of all the
patients in the group by the number of patients in the group. The registered cause of death was determined by reference
to the death registry records at New Register House, Edin-
burgh.
Table I Part of the abridged life table for Scottish males 1987
Age x I'a eb
0 10,000 70.47
5 9,886 66.28
20 9,820 51.66
40 9,588 32.64
45 9,446 28.09
50 9,222 23.72
55 8,823 19.67
60 8,192 16.00
65 7,210 12.84
70 5,933 10.06
75 4,347 7.82
80 2,729 5.97
85 1,340 4.57
aThe numbers who would survive to age x of 10,000 males exposed
throughout life to the mortality probabilities indicated by the death
records for 1987. bThe average numberofyears oflifeleft to menaged x
exposed to 1987 mortality probabilities from age x.
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Figure 1 Survival curve representing data from the abridged life
table for Scottish males 1987.
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Figure 2 Probability of survival at 5 and 10 years as a function
of age. Based on abridged life table for Scottish males 1987.
Results
Of the total 438 patients, 249 (57%) had died by September
1988. Duration of follow-up, to death or to date, ranged
from 20 days (the earliest death) to 10 years 8 months (mean
2.75 years). Sixty-seven patients remained at risk 5 years after
diagnosis.
The mean age of the group was 72.5 (range 45.3-91.0
years). The age profile of all patients in the series is shown in
Figure 3 and that for all new registrations of carcinoma of
the prostate in Scotland in the 5 years 1979-83 is superim-
posed for comparison.
The overall probability of survival at 5 years (all causes of
death) calculated by life table methods is 33.1%. The
expected survival rates at 5 years for an exactly age-matched
group (calculated as described above) is 65.5%. Thus the
relative survival rate at 5 years in the entire group is 50.5%,
implying that half of the observed mortality was due to
concurrent disease. The relative survival rate at 5 years is
seen to vary with age (Table 1I), increasing from 41% in the
45-54 age group to 58% in the 75-84 age group. This may
be interpreted as showing a greater relative impact of pros-
tate cancer on survival of the younger patient. To what
degree this is due to the increasing frequency of serious
concurrent disease with age or to some difference in the
malignant potential of the tumour in the younger patient is
not easily deduced from these data.
Causes of death according to death certification are shown
in Figure 4. Sixty-two per cent of the deaths were attributed
directly to prostate cancer or to conditions arising as a result
of prostate cancer. Of those whose deaths were attributed to
causes other than prostate cancer, in 59% prostate cancer
was not mentioned in section II of the certificate (other
co-existent conditions), suggesting that the certifying doctor
was unaware of the diagnosis. The cancer specific death rate
(calculated by life table methods) according to the certified
cause of death is shown in Figure 5 with expected rates and
overall death rate for comparison.
Figure 3 Age distribution of 438 new cases of prostate cancer
(WGH) and the age distribution of all new registrations of pros-
tate cancer in Scotland (1979-83).
Table II Observed, expected and relative 5-year survival of prostate
cancer patients grouped by age
Expected Observed Relative
Age % % 0
45-54 94.6 38.5 40.7
55-64 85.7 42.6 49.7
65-74 72.6 40.0 55.2
75-84 51.8 29.9 57.7
All 65.5 33.1 50.5
Other
causes 5%
Cerebrovascular disease 13%
Respiratory disease 6%N
Heart disease 13%
Other malignant
neoplasms 7% .
Prostate
cancer 62%
Figure 4 Certified causes of death.
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Figure 5 Actuarial survival curves showing deaths due to all
causes, deaths certified as due to prostate cancer, and expected
death rates at 5 and 10 years.
Since patients were assessed in a specific prostate cancer
clinic until shortly before death, data available from the
pre-death visits were assessed to try to identify patients with
signs of systemically progressive disease that might be con-
sidered likely to have led to death. Forty-six patients had
rapidly rising acid phosphatase (defined here as increasing by
a factor of > 1.8, within the abnormal range, twice in the 6
months up to pre-death visit) or alkaline phosphatase
(defined as increasing during the 6 months up to pre-death
visit by a factor of > 1.5, final value > 3 times upper limit
of normal), or both, in the 6 months before the pre-death
visit (Figure 6). These definitions are accepted as being essen-
tially arbitrary, but the limits used appeared most effectively
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Figure 6 Serum alkaline (a) and acid (b) phosphatase in the 6
months up to the final pre-death visit of 46 patients with 'rising
markers' (11 patients were in both groups).
to separate those with stable markers from those whose
markers were increasing before death. All but one of these
patients were known to have skeletal metastases at the time
of death. A further 19 patients had a steadily rising blood
urea (defined here as increasing twice by a factor of > 1.5,
within the abnormal range, in the 6 months up to the pre-
death visit). Of these 65 patients with biochemical evidence of
progressing disease, 90% were certified as having died of
prostate cancer.
Of the remaining 184 patients, 34 died in less than 6
months and so could not satisfy the criteria for 'rising
markers'. Eighty-seven (47%) were certified as dying from
prostatic cancer. Most of these had evidence of advanced,
but stable, disease before death, but 10 patients had no
evidence of skeletal metastases, and normal blood urea, acid
and alkaline phosphatase at the pre-death visit.
Discussion
Each of the methods used to measure and express disease
specific mortality in prostate cancer considered here has some
value and each has different disadvantages. These will be
discussed in turn.
The value of the relative survival rate depends on the
accuracy of the expected survival data, and on how closely
the population studied matches that used to compute the
expected survival rate. The age distribution of patients with
prostate cancer is very different from the age distribution of
the general population. Expected survival figures based on
mortality in the general population must therefore be con-
trasted with care to observed survival in patients with pros-
tate cancer. Here we have used 'exact age matching' to derive
expected survival figures. In terms of age at presentation our
series closely reflects the rates of registration in the local
community, and the population studied is relatively static,
most patients having lived all their lives locally. We believe
that relative survival rates computed from these figures give
the most objective, if indirect, measure of prostate cancer
related mortality in such a group.
The data from which the figures are derived are readily
accessible and the method used can be applied to any group
of patients, but is clearly most applicable when considering
mortality from diseases which occur, in part, in elderly
patients. The main advantage of using relative survival to
express mortality in prostate cancer lies in its objectivity,
since no decision has to be made about each individual cause
of death. The main disadvantage is that when the study
population is made up of individuals from very different
communities (for instance in a tertiary referral centre) the
available expected survival data may be inappropriate.
As may be expected, the certified cause of death is, at best,
a crude measure of disease specific mortality and it would
seem that most authors are correct in avoiding the use of
death certification when reporting survival. There were a
number of major discrepancies identified in this study. In 10
patients (4% of those dying) clinic data suggested neither
advanced nor progressive disease, and yet prostate cancer
was given as the cause of death on the death certificate, while
in 37% of those dying, prostate cancer was not mentioned on
any part of the death certificate. In this series the death
certificate was most often completed by the patient's general
practitioner (who is regularly informed of his patient's pro-
gress from the prostate clinic) and so the degree of con-
sistency in death certification data might be expected to be
even lower in regions not having a dedicated prostate cancer
follow-up clinic.
Despite these inconsistencies, the 'cancer specific' pro-
bability of survival at 5 years calculated from the certification
data is 51.1% (Figure 5), closely matching the relative sur-
vival rate at 5 years of 50.5%. Published national mortality
rates (based on certification data) have in recent years
remained close to 50% of the rate of new registrations of
prostate cancer (Wilson, 1987), and it is interesting to note
that this observation is reflected in the relative survival rate
in this series. This suggests that the certification data,
although inaccurate on a relatively small scale, may begin to
approximate to the genuine situation on a national scale.
Since 'referral to the hospital records' is often used to
determine cause of death we were interested to see how easily
a decision could be made on the basis of our own close
observation of patients before death. It proved very difficult
to define a set of conditions that could imply a 'cancer
death'. While all urologists have witnessed patients in the
terminal stages of advanced prostatic cancer and may have
been well able to conclude that their patient was dying of his
prostatic malignancy, the hospital record is only rarely so
unequivocal.
In the absence of documented concurrent serious disease,
the rising biochemical markers described here suggest a prob-
able cancer specific death, but no more, and we would con-
clude that apart from the occasional extreme example it is
not possible to identify a 'cancer death' on the basis of
retrospective records.
George (1988) referred to hospital records in order to
identify deaths from 'verified conditions other than prostate
cancer' and these were identified as non-cancer deaths in his
series. In reviewing causes of death in our series, it has
proved very difficult to identify causes that exclude prostate468 C.M. GOODMAN et al.
cancer from contributing to the cause of death. In our series
there were 17 deaths 'due to' other malignant neoplasms, 24
to acute myocardial infarction, one to complication of a
strangulated inguinal hernia, one to rupture of an abdominal
aortic aneurysm and one to alcohol induced hepatic cirrhosis.
Some of these lethal processes may have been entirely
independent of prostate cancer but others may not. To give
one instance, three of these certified of dying of cerebrovas-
cular or cardiovascular catastrophe had been previously
treated with stilboestrol. It would be wrong not to accept
that prostatic cancer may have contributed significantly to
such deaths.
The possible criteria used to attribute causes to deaths on
the basis of hospital records are complex and thus difficult to
define and reproduce. Furthermore, if the criteria used can-
not be clearly defined, interpretation of the hospital record is
open to subjective bias and cannot therefore be recom-
mended for use in the calculation of disease specific mor-
tality.
In conclusion, the interpretation of reports of survival in
prostate cancer would be facilitated by the reporting of the
expected survival (calculated in a clearly defined manner on
the best available population data) of each group considered.
This single statistic takes into account the age of each indi-
vidual in the group and best describes the age related general
mortality in the group. It can be compared directly between
reports from different centres, allowing the reader to judge
how much any difference in observed mortality is due to
prostate cancer and its treatment, and how much is due to
difference in general mortality. Relative survival at a given
time can be easily computed and used as an indirect but
objective expression of cancer specific mortality.
The reporting of cancer specific mortality based on using
retrospective records to identify 'cancer deaths' and 'deaths
due to other causes' is of limited value, since the criteria used
cannot be simply defined in a reproducible manner. Death
certification data are confirmed to be inaccurate in the con-
text of prostate cancer mortality studies and should continue
to be avoided. Reports of mortality and survival which fail to
give any information on patient age cannot be interpreted
sensibly.
We gratefully acknowledge the valuable assistance of the staff of
New Register House, Edinburgh, and thank the Registrar General
for Scotland for permission to publish data derived from the death
registry. We are grateful to Mr J.E. Newsam and Mr T.B. Hargreave
for their consent to report on patients in their care and to Dr R.A.
Elton of the Medical Statistics Unit of the University of Edinburgh
for advice.
References
ANNUAL REPORTS OF THE REGISTRAR GENERAL FOR SCOT-
LAND (1978-87). Numbers 123-133. HMSO: London.
ARMITAGE, P. & BERRY, G. (1987). Survival analysis. In Statistical
Methods in Medical Research, 2nd edn., p. 241. Blackwell: Oxford.
GEORGE, N.J.R. (1988). Natural history of localised prostatic cancer
managed by conservative therapy alone. Lancet, i, 494.
GOODMAN, C.M., BUSUTTIL, A. & CHISHOLM, G.D. (1988). Age,
and size and grade of tumour predict prognosis in incidentally
diagnosed carcinoma of the prostate. Br. J. Urol., 62, 576.
JOHANSSON, J., ADAMI, H., ANDERSSON, S., BERGSTROM, R.,
KRUSEMO, U.B. & KRAAZ, W. (1989). Natural history of
localised prostatic cancer. A population based study in 223 un-
treated patients. Lancet, i, 799.
MERRICK, M.V., DING, C.L., CHISHOLM, G.D & ELTON, R.A. (1985).
Prognostic significance of alkaline and acid phosphatase and
skeletal scintigraphy in carcinoma of the prostate. Br. J. Urol.,
57, 715.
PARKER, M.C., COOK, A., RIDDLE, P.R., FRYATT, I., O'SULLIVAN, J.
& SHEARER, R.J. (1985). Is delayed treatment justified in car-
cinoma of the prostate? Br. J. Urol., 57, 724.
PAULSON, D.F. & WALTHER, P.J. (1989). Is grade or stage of
primary importance in determining the outcome after radical
prostatectomy for disease clinically confined to the prostate? Br.
J. Urol., 63, 301.
PETO, R., PIKE, M.C., ARMITAGE, P. & 7 others (1977). Design and
analysis of randomised clinical trials which require prolonged
observation of each patient. II. Analysis and examples. Br. J.
Cancer, 35, 1
WILSON, J.M.G. (1987). Epidemiology of adenocarcinoma of the
prostate. In Adenocarcinoma of the Prostate, Bruce, A.W. &
Trachtenberg, J. (eds) p. 2. Springer-Verlag: Berlin.
WILSON, J.M.G., KEMP, I.W. & STEIN, G.J. (1984). Cancer of the
prostate. Do younger men have a poorer survival rate? Br. J.
Urol., 56, 391.